UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Frontiers in immunology, 2018-07, Vol.9, p.1739-1739

2018

Volltextzugriff (PDF)

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma

Mayo Clinic proceedings, 2014-04, Vol.89 (4), p.504-519

2014

Volltextzugriff (PDF)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy

American journal of reproductive immunology (1989), 2018-02, Vol.79 (2), p.n/a

2018

Volltextzugriff (PDF)

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

Oncoimmunology, 2020-01, Vol.9 (1), p.1744980-1744980

2020

Volltextzugriff (PDF)

The use of pembrolizumab for the treatment of metastatic uveal melanoma

Melanoma research, 2016-06, Vol.26 (3), p.300-303

2016

Volltextzugriff (PDF)

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

PloS one, 2020-03, Vol.15 (3), p.e0230306-e0230306

2020

Volltextzugriff (PDF)

Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma

Mayo Clinic proceedings, 2014-04, Vol.89 (4), p.520-535

2014

Volltextzugriff (PDF)

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Nature communications, 2024-02, Vol.15 (1), p.1430-1430, Article 1430

2024

Volltextzugriff (PDF)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

Journal for immunotherapy of cancer, 2020-08, Vol.8 (2), p.e001113

2020

Volltextzugriff (PDF)

Immune Checkpoint Inhibitor Toxicities

Mayo Clinic proceedings, 2019-07, Vol.94 (7), p.1321-1329

2019

Volltextzugriff (PDF)

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma

International journal of molecular sciences, 2017-11, Vol.18 (11), p.2326

2017

Volltextzugriff (PDF)

Increasing Incidence of Melanoma Among Middle-Aged Adults: An Epidemiologic Study in Olmsted County, Minnesota

Mayo Clinic proceedings, 2014, Vol.89 (1), p.52-59

2014

Volltextzugriff (PDF)

Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation

Mayo Clinic proceedings, 2012-10, Vol.87 (10), p.976-981

2012

Volltextzugriff (PDF)

NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm

Journal of thoracic oncology, 2013-10, Vol.8 (10), p.1335-1338

2013

Volltextzugriff (PDF)

Effect of β-Adrenergic Blockers and Other Antihypertensive Drugs on the Risk of Melanoma Recurrence and Death—I

Mayo Clinic proceedings, 2014-08, Vol.89 (8), p.1164-1165

2014

Volltextzugriff (PDF)

Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

The oncologist (Dayton, Ohio), 2019-11, Vol.24 (11), p.e1148-e1155

2019

Volltextzugriff (PDF)

Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications

Mayo Clinic proceedings. Innovations, quality & outcomes, 2021-06, Vol.5 (3), p.645-653

2021

Volltextzugriff (PDF)

Contraction of T cell richness in lung cancer brain metastases

Scientific reports, 2018-02, Vol.8 (1), p.2171-9, Article 2171

2018

Volltextzugriff (PDF)

Immunomodulatory antibody therapy of cancer: the closer, the better

Clinical cancer research, 2015-03, Vol.21 (5), p.944-946

2015

Volltextzugriff (PDF)

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Melanoma research, 2020-08, Vol.30 (4), p.364-375

2020

Volltextzugriff (PDF)

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma

Advances in radiation oncology, 2017-04, Vol.2 (2), p.204-210

2017

Volltextzugriff (PDF)

A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis

Prostate cancer and prostatic diseases, 2024-02

2024

Volltextzugriff (PDF)

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011

Cancer medicine (Malden, MA), 2017-10, Vol.6 (10), p.2203-2212

2017

Volltextzugriff (PDF)

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

JCI insight, 2018-04, Vol.3 (8)

2018

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(139)

Publikationsform

Sprache

Englisch
(175)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

The use of pembrolizumab for the treatment of metastatic uveal melanoma

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

Immune Checkpoint Inhibitor Toxicities

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma

Increasing Incidence of Melanoma Among Middle-Aged Adults: An Epidemiologic Study in Olmsted County, Minnesota

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation

NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm

Effect of β-Adrenergic Blockers and Other Antihypertensive Drugs on the Risk of Melanoma Recurrence and Death—I

Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications

Contraction of T cell richness in lung cancer brain metastases

Immunomodulatory antibody therapy of cancer: the closer, the better

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma

A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Suchergebnisse filtern